SCHEMBL4484870

SCHEMBL4484870

CCCCNC(=O)Cc1ccc2c(c1)C(O)=C(N)C(C)(C)O2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ TRPV1 Q8NER1 1/20 0.48
▸ HPGD P15428 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HDAC4 P56524 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ PABPC1 P11940 1/20 0.35
▸ CNR1 P21554 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4481443 0.82 MEN1 (0.48) CA1CA2HPGDALDH1A1MEN1
SCHEMBL4478602 0.77 CA1 (0.44) CA1CA2TRPV1HPGDALDH1A1
SCHEMBL5088894 0.75 TRPV1 (0.68) CA1CA2TRPV1HPGDKDM4E
SCHEMBL4471596 0.72 HPGD (0.50) CA1CA2TRPV1HPGDALDH1A1
SCHEMBL4470956 0.72 CA1 (0.47) CA1CA2TRPV1HPGDHDAC4
SCHEMBL4492535 0.70 CA1 (0.47) CA1CA2TRPV1HPGDALDH1A1
SCHEMBL9614625 0.68 HPGD (0.76) CA1CA2TRPV1HPGDALDH1A1
SCHEMBL11626374 0.68 HPGD (0.57) CA1CA2TRPV1HPGDKDM4E
SCHEMBL5089884 0.67 TRPV1 (0.59) CA1CA2TRPV1HPGDALDH1A1
SCHEMBL10548485 0.66 TRPV1 (1.00) CA1CA2TRPV1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534903-B2 Use of amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl-compounds in the treatment of cardiac arrhythmia and other disease states SOLVAY PHARMACEUTICALS GMBH (DE) 2009-05-19 — — US disclosed
US-20080113999-A1 Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States SOLVAY PHARMACEUTICALS GMBH (DE) 2008-05-15 — — US disclosed
US-7368582-B2 Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2008-05-06 — — US disclosed
US-20050148659-A1 Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2005-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148659-A1 Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, CYP3A4 CA1 4689/4885CA2 3695/4885TRPV1 3870/4885
US-20080113999-A1 Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States KCNH1, RYR2, KCNJ2 CA1 3342/4885CA2 1236/4885TRPV1 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback